Genextra

Genextra

Identify innovative research in life science and develop novel therapies and tools.

  • Edit
DateInvestorsAmountRound
-

N/A

-
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2015201620172018201920202021
Revenues0000000000000000000000000000
EBITDA0000000000000000000000000000
Profit0000000000000000000000000000
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article

More about Genextra
Made with AI
Edit

Genextra is a privately owned holding company specializing in investments in early-stage life science companies. Founded in 2004 and based in Italy, Genextra focuses on identifying innovative research in the life sciences sector and advancing novel therapies and tools through strategic business initiatives. The company operates without territorial limits but benefits from preferential access to high-quality Italian-based science. Genextra's business model involves seeking and fostering life sciences investment opportunities, as well as building the necessary infrastructure and management teams to facilitate growth. The company generates revenue through equity investments in promising startups and early-stage companies, aiming to create value for its shareholders. Genextra serves a diverse range of clients, including researchers, entrepreneurs, and other stakeholders in the life sciences ecosystem.

Keywords: life sciences, early-stage investments, innovative therapies, holding company, Italian-based science, strategic initiatives, infrastructure development, management support, equity investments, shareholder value.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Genextra

Edit
Erydel
ACQUISITION by Quince Therapeutics Oct 2023
Intercept Pharmaceuticals
ACQUISITION by Alfasigma Sep 2023